Portable, shelf-stable
Additionally, cardiovascular outcome trials have shown reductions in major adverse cardiac events with GLP-1 therapies
Modern pharmacologic approaches allow the relative contribution of each receptor to be quantitatively tuned, mitigating adverse effects while preserving efficacy (Finan et al., 2016)
Glucagon-like peptide-1 receptor agonists
Glucagon-like peptide-1 receptor (GLP-1R) is a member of the glucagon-like receptor subfamily of the G protein-coupled receptor B family and is widely expressed in the cardiovascular system, brain, hypothalamus, hippocampus, kidney, liver, lung, digestive tract, pancreas, fat and skeletal muscle ( Due to the wide distribution of GLP-1R, the pharmacological effects of GLP-1RA after interaction with receptors are also extremely extensive
Furthermore, this review highlighted the importance of maintaining the integrity of RGCs, a critical group of neurons that integrate the central nervous system with the visual apparatus which are an area of dysfunction in both DR and glaucoma
